MIC distribution analysis identifies differences in AMR between population sub-groups
Open Access
- 9 May 2024
- journal article
- research article
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 9, 244
Abstract
Background Phenotypic data, such as the minimum inhibitory concentrations (MICs) of bacterial isolates from clinical samples, are widely available through routine surveillance. MIC distributions inform antibiotic dosing in clinical care by determining cutoffs to define isolates as susceptible or resistant. However, differences in MIC distributions between patient sub-populations could indicate strain variation and hence differences in transmission, infection, or selection. Methods The Vivli AMR register contains a wealth of MIC and metadata for a vast range of bacteria-antibiotic combinations. Using a generalisable methodology followed by multivariate regression, we explored MIC distribution variations across 4 bacteria, covering 7,135,070 samples, by key population sub-groups such as age, sex and infection type, and over time. Results We found clear differences between MIC distributions across various patient sub-groups for a subset of bacteria-antibiotic pairings. For example, within Staphylococcus aureus, MIC distributions by age group and infection site displayed clear trends, especially for levofloxacin with higher resistance levels in older age groups (odds of 2.17 in those aged 85+ compared to 19–64), which appeared more often in men. This trend could reflect greater use of fluoroquinolones in adults than children but also reveals an increasing MIC level with age, suggesting either transmission differences or accumulation of resistance effects. We also observed high variations by WHO region, and over time, with the latter likely linked to changes in surveillance. Conclusions We found that MIC distributions can be used to identify differences in AMR levels between population sub-groups. Our methodology could be used more widely to unveil hidden transmission sources and effects of antibiotic use in different patient sub-groups, highlighting opportunities to improve stewardship programmes and interventions, particularly at local scales.Keywords
Funding Information
- Medical Research Council (MR/W026643/1, MR/N013638/1)
- Biotechnology and Biological Sciences Research Council (BB/M009513/1)
- Wellcome (227486)
This publication has 28 references indexed in Scilit:
- Changing times: The impact of gram-negative breakpoint changes over the previous decadeAntimicrobial Stewardship & Healthcare Epidemiology, 2022
- Seeking patterns of antibiotic resistance in ATLAS, an open, raw MIC database with patient metadataNature Communications, 2022
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysisThe Lancet, 2022
- Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019Journal of Global Antimicrobial Resistance, 2021
- AMR in low-resource settings: Médecins Sans Frontières bridges surveillance gaps by developing a turnkey solution, the Mini-LabClinical Microbiology and Infection, 2021
- Characterization of antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countriesNature Microbiology, 2021
- Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet Infectious Diseases, 2018
- Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016The Lancet Infectious Diseases, 2018
- Antimicrobial ResistanceMedical Clinics of North America, 2018
- Safety Concerns Surrounding Quinolone Use in ChildrenThe Journal of Clinical Pharmacology, 2016